These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1416832)

  • 1. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae.
    Arai S; Gohara Y; Kuwano K; Kawashima T
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1322-4. PubMed ID: 1416832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro antimicrobial activities of new quinolone antibiotics against Mycoplasma pneumoniae].
    Gohara Y; Arai S; Kuwano K; Kawashima T; Matsu-Ura I
    Nihon Saikingaku Zasshi; 1992 Mar; 47(2):387-93. PubMed ID: 1318981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Ikejima H; Yamamoto H; Ishida K; Kaku M; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):148-50. PubMed ID: 11810555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides.
    Samra Z; Rosenberg S; Soffer Y
    Diagn Microbiol Infect Dis; 2002 Dec; 44(4):359-61. PubMed ID: 12543541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.
    Fenelon LE; Mumtaz G; Ridgway GL
    J Antimicrob Chemother; 1990 Dec; 26(6):763-7. PubMed ID: 2081718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 2001 Sep; 45(9):2604-8. PubMed ID: 11502536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Susceptibility to macrolides against Mycoplasma pneumoniae isolated during 7 years].
    Arai S; Ohishi M; Shigematsu H
    Kansenshogaku Zasshi; 1994 Feb; 68(2):201-8. PubMed ID: 8151146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimycoplasmal activity of ofloxacin (DL-8280).
    Osada Y; Ogawa H
    Antimicrob Agents Chemother; 1983 Mar; 23(3):509-11. PubMed ID: 6573869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing Antimicrobial Susceptibilities among
    Oishi T; Takahashi K; Wakabayashi S; Nakamura Y; Ono S; Kono M; Kato A; Saito A; Kondo E; Tanaka Y; Teranishi H; Akaike H; Tanaka T; Miyata I; Ogita S; Ohno N; Nakano T; Ouchi K
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.
    Waites KB; Cassell GH; Canupp KC; Fernandes PB
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1500-2. PubMed ID: 2973283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Sato K
    J Infect Chemother; 2000 Sep; 6(3):188. PubMed ID: 11810563
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
    Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
    Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Mar; 35(3):587-9. PubMed ID: 1903913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in the macrolides and quinolones.
    Boswell FJ; Wise R
    Infect Dis Clin North Am; 1998 Sep; 12(3):647-70. PubMed ID: 9779383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibiotic susceptibility of Mycoplasma fermentans strains from various sources and the development of resistance to aminoglycosides in vitro.
    Hannan PC
    J Med Microbiol; 1995 Jun; 42(6):421-8. PubMed ID: 7791207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.
    Pudjiatmoko ; Fukushi H; Ochiai Y; Yamaguchi T; Hirai K
    Microbiol Immunol; 1998; 42(1):61-3. PubMed ID: 9525782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics.
    Bébéar C; Pereyre S; Peuchant O
    Future Microbiol; 2011 Apr; 6(4):423-31. PubMed ID: 21526943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.